



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Cannabis and cannabinoids in dermatology: protocol for a systematic review and meta-analysis of quantitative outcomes.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-075007
Article Type:	Protocol
Date Submitted by the Author:	24-Apr-2023
Complete List of Authors:	Sermsaksasithorn, Pim; Chulalongkorn University Faculty of Medicine Nopsohon, Tanawin; Brigham and Women's Hospital Department of Medicine Samuthpongton, Chatpol; Chulalongkorn University Faculty of Medicine Chotirosniramit, Korn; Chulalongkorn University Faculty of Medicine Pongpirul, Krit; Chulalongkorn University Faculty of Medicine, Preventive and Social Medicine; Johns Hopkins University Bloomberg School of Public Health, International Health
Keywords:	Dermatology < INTERNAL MEDICINE, COMPLEMENTARY MEDICINE, Psoriasis < DERMATOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37

Cannabis and cannabinoids in dermatology: protocol for a systematic review and meta-analysis of quantitative outcomes.

Pim Sermasaksathorn^{1,2}, Tanawin Nopsopon^{1,2,3}, Chatpol Samuthpongton^{1,2}, Korn Chotirosniramit^{1,2}, Krit Pongpirul^{1,2,4,5,6*}

¹ Department of Preventive and Social Medicine, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand.
² School of Global Health, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand.
³ Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, United States.
⁴ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
⁵ Department of Infection Biology & Microbiomes, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.
⁶ Clinical and Research Center, Bumrungrad International Hospital, Bangkok, Thailand.

* Corresponding author Email: doctorkrit@gmail.com

Abstract

Following the discovery of various effects on skin function by modifying endocannabinoid systems, multiple preclinical studies have revealed the promise of cannabis and cannabinoids in the treatment of a variety of skin diseases. However, its clinical efficacy is still debated. This systematic review aims to evaluate the therapeutic efficacy of cannabis and cannabinoids in dermatological conditions and diseases. The protocol has been prepared using the Preferred Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines and has been registered with the International Prospective Register of Systematic Reviews (PROSPERO: CRD42023397189). PubMed, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science will be used for the systemic search. The outcomes will be an improvement in dermatological characteristics, including disease-specific composite scores and objective and subjective outcomes of skin conditions. This systematic review will provide valuable information on dermatological therapy of cannabis and cannabinoids and could be the start of future research and medicinal applications.

Introduction

Skin is the largest human organ and is essential for organism survival. It is the first line of immunological and physical protection against the external environment, including heat control and retention of hydration [1, 2]. A substantial part of the population is affected by skin diseases that have significant effects on the quality of life of sufferers (3-7).

The Endocannabinoid System (ECS), which includes receptors, ligands, and enzymes, is mainly responsible for maintaining homeostasis and the balance of multiple biological functions in the nervous system and peripheral organs [3-5]. Cannabinoids and active components of *Cannabis sativa*, which were found to mimic endocannabinoid signaling and influence receptor expression [6, 7], have gained interest as potential treatment for various diseases [3, 5]. The growing legalization of medicinal cannabis and cannabinoids led to the search for medicinal use in clinical practice. The FDA currently approves the use of cannabinoid to alleviate pain and spasticity in multiple sclerosis and the treatment of chemotherapy-induced nausea and vomiting in cancer patients [8-11].

Modulation of the activity of the endocannabinoid system has been shown to influence several types of skin disease, including atopic dermatitis, psoriasis, acne, and skin tumors, according to the etiology of the diseases [12-15]. Furthermore, cannabis has anti-inflammatory and anti-pruritic properties [10, 16-18]. This makes the cannabinoids and active components of *Cannabis sativa* promising for the therapeutic treatment of the skin disorders mentioned above. Given the insufficient quality clinical studies on this topic, this systematic review aims to examine the efficacy of cannabis and cannabinoids in alleviating dermatological conditions and diseases by highlighting current and historical attempts to collect robust clinical data and identify knowledge gaps.

Material and methods

The systematic review protocol was registered with the International Prospective Register of Systematic Reviews (PROSPERO) on February 17th, 2023 (CRD42023397189). The protocol followed the Preferred Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines.

Study Selection

Any randomized controlled trials and observational studies including cross-sectional studies, case-control studies, or cohort studies that investigate the efficacy or effectiveness of any form of medical cannabis or cannabinoid in alleviating dermatological conditions or diseases will be included. Exclusion criteria are (1) in vitro studies, case report, protocol, review article, guideline, editorial, commentary, and letter to editor (2) non-peer-reviewed studies (3) animal studies (4) studies published in non-English. Human participants of all ages will be included. The intervention includes an application of cannabis or cannabinoids in any preparation through any route. Study with placebo control, active control, or even no control will be assessed.

1

2 80

3 81

4 82

5 83

6 84

7 85

8 86

9 87

10 88

11 89

12 90

13 91

14 92

15 93

16 94

17 95

18 96

19 97

20 98

21 99

22 100

23 101

24 102

25 103

26 104

27 105

28 106

29 107

30 108

31 109

32 110

33 111

34 112

35 113

36 114

37 115

38 116

39 117

40 118

41 119

42 120

43 121

44 122

45 123

46 124

47 125

48 126

49 127

50 128

51 129

52 130

53 131

54 132

55 133

56 134

57 135

58 136

59 137

60 138

61 139

62 140

63 141

64 142

65 143

66 144

67 145

68 146

69 147

70 148

71 149

72 150

73 151

74 152

75 153

76 154

77 155

78 156

79 157

80 158

81 159

82 160

83 161

84 162

85 163

86 164

87 165

88 166

89 167

90 168

91 169

92 170

93 171

94 172

95 173

96 174

97 175

98 176

99 177

100 178

101 179

102 180

103 181

104 182

105 183

106 184

107 185

108 186

109 187

110 188

111 189

112 190

113 191

114 192

115 193

116 194

117 195

118 196

119 197

120 198

121 199

122 200

123 201

124 202

125 203

126 204

127 205

128 206

129 207

130 208

131 209

132 210

133 211

134 212

135 213

136 214

137 215

138 216

139 217

140 218

141 219

142 220

143 221

144 222

145 223

146 224

147 225

148 226

149 227

150 228

151 229

152 230

153 231

154 232

155 233

156 234

157 235

158 236

159 237

160 238

161 239

162 240

163 241

164 242

165 243

166 244

167 245

168 246

169 247

170 248

171 249

172 250

173 251

174 252

175 253

176 254

177 255

178 256

179 257

180 258

181 259

182 260

183 261

184 262

185 263

186 264

187 265

188 266

189 267

190 268

191 269

192 270

193 271

194 272

195 273

196 274

197 275

198 276

199 277

200 278

201 279

202 280

203 281

204 282

205 283

206 284

207 285

208 286

209 287

210 288

211 289

212 290

213 291

214 292

215 293

216 294

217 295

218 296

219 297

220 298

221 299

222 300

223 301

224 302

225 303

226 304

227 305

228 306

229 307

230 308

231 309

232 310

233 311

234 312

235 313

236 314

237 315

238 316

239 317

240 318

241 319

242 320

243 321

244 322

245 323

246 324

247 325

248 326

249 327

250 328

251 329

252 330

253 331

254 332

255 333

256 334

257 335

258 336

259 337

260 338

261 339

262 340

263 341

264 342

265 343

266 344

267 345

268 346

269 347

270 348

271 349

272 350

273 351

274 352

275 353

276 354

277 355

278 356

279 357

280 358

281 359

282 360

283 361

284 362

285 363

286 364

287 365

288 366

289 367

290 368

291 369

292 370

293 371

294 372

295 373

296 374

297 375

298 376

299 377

300 378

301 379

302 380

303 381

304 382

305 383

306 384

307 385

308 386

309 387

310 388

311 389

312 390

313 391

314 392

315 393

316 394

317 395

318 396

319 397

320 398

321 399

322 400

323 401

324 402

325 403

326 404

327 405

328 406

329 407

330 408

331 409

332 410

333 411

334 412

335 413

336 414

337 415

338 416

339 417

340 418

341 419

342 420

343 421

344 422

345 423

346 424

347 425

348 426

349 427

350 428

351 429

352 430

353 431

354 432

355 433

356 434

357 435

358 436

359 437

360 438

361 439

362 440

363 441

364 442

365 443

366 444

367 445

368 446

369 447

370 448

371 449

372 450

373 451

374 452

375 453

376 454

377 455

378 456

379 457

380 458

381 459

382 460

383 461

384 462

385 463

386 464

387 465

388 466

389 467

390 468

391 469

392 470

393 471

394 472

395 473

396 474

397 475

398 476

399 477

400 478

401 479

402 480

403 481

404 482

405 483

406 484

407 485

408 486

409 487

410 488

411 489

412 490

413 491

414 492

415 493

416 494

417 495

418 496

419 497

420 498

421 499

422 500

423 501

424 502

425 503

426 504

427 505

428 506

429 507

430 508

431 509

432 510

433 511

434 512

435 513

436 514

437 515

438 516

439 517

440 518

441 519

442 520

443 521

444 522

445 523

446 524

447 525

448 526

449 527

450 528

451 529

452 530

453 531

454 532

455 533

456 534

457 535

458 536

459 537

460 538

461 539

462 540

463 541

464 542

465 543

466 544

467 545

468 546

469 547

470 548

471 549

472 550

473 551

474 552

475 553

476 554

477 555

478 556

479 557

480 558

481 559

482 560

483 561

484 562

485 563

486 564

487 565

488 566

489 567

490 568

491 569

492 570

493 571

494 572

495 573

496 574

497 575

498 576

499 577

500 578

501 579

502 580

503 581

504 582

505 583

506 584

507 585

508 586

509 587

510 588

511 589

512 590

513 591

514 592

515 593

516 594

517 595

518 596

519 597

520 598

521 599

522 600

523 601

524 602

525 603

526 604

527 605

528 606

529 607

530 608

531 609

532 610

533 611

534 612

535 613

536 614

537 615

538 616

539 617

540 618

541 619

542 620

543 621

544 622

545 623

546 624

547 625

548 626

549 627

550 628

551 629

552 630

553 631

554 632

555 633

556 634

557 635

558 636

559 637

560 638

561 639

562 640

563 641

564 642

565 643

566 644

567 645

568 646

569 647

570 648

571 649

572 650

573 651

574 652

575 653

576 654

577 655

578 656

579 657

580 658

581 659

582 660

583 661

584 662

585 663

586 664

587 665

588 666

589 667

590 668

591 669

592 670

593 671

594 672

595 673

596 674

597 675

598 676

599 677

600 678

601 679

602 680

603 681

604 682

605 683

606 684

607 685

608 686

609 687

610 688

611 689

612 690

613 691

614 692

615 693

616 694

617 695

618 696

619 697

620 698

621 699

622 700

623 701

624 702

625 703

626 704

627 705

628 706

629 707

630 708

631 709

632 710

633 711

634 712

635 713

636 714

637 715

638 716

639 717

640 718

641 719

642 720

643 721

644 722

645 723

646 724

647 725

648 726

649 727

650 728

651 729

652 730

653 731

654 732

655 733

656 734

657 735

658 736

659 737

660 738

661 739

662 740

663 741

664 742

665 743

666 744

667 745

668 746

669 747

670 748

671 749

672 750

673 751

674 752

675 753

676 754

677 755

678 756

679 757

680 758

681 759

682 760

683 761

684 762

685 763

686 764

687 765

688 766

689 767

690 768

691 769

692 770

693 771

694 772

695 773

696 774

697 775

698 776

699 777

700 778

701 779

702 780

703 781

704 782

705 783

706 784

707 785

708 786

709 787

710 788

711 789

712 790

713 791

714 792

715 793

716 794

717 795

718 796

719 797

720 798

721 799

722 800

723 801

724 802

725 803

726 804

727 805

728 806

729 807

730 808

731 809

732 810

733 811

734 812

735 813

736 814

737 815

738 816

739 817

740 818

741 819

742 820

743 821

744 822

745 823

746 824

747 825

748 826

749 827

750 828

751 829

752 830

753 831

754 832

755 833

756 834

757 835

758 836

759 837

760 838

761 839

762 840

763 841

764 842

765 843

766 844

767 845

768 846

769 847

770 848

771 849

772 850

773 851

774 852

775 853

776 854

777 855

778 856

779 857

780 858

781 859

782 860

783 861

784 862

785 863

786 864

787 865

788 866

789 867

790 868

791 869

792 870

793 871

794 872

795 873

796 874

797 875

798 876

799 877

800 878

801 879

802 880

803 881

804 882

805 883

806 884

807 885

808 886

809 887

810 888

811 889

812 890

813 891

814 892

815 893

816 894

817 895

818 896

819 897

820 898

821 899

822 900

823 901

824 902

825 903

826 904

827 905

828 906

829 907

830 908

831 909

832 910

833 911

834 912

835 913

836 914

837 915

838 916

839 917

840 918

841 919

842 920

843 921

844 922

845 923

846 924

847 925

848 926

849 927

850 928

851 929

852 930

853 931

854 932

855 933

856 934

857 935

858 936

859 937

860 938

861 939

862 940

863 941

864 942

865 943

866 944

867 945

868 946

869 947

870 948

871 949

872 950

873 951

874 952

875 953

876 954

877 955

878 956

879 957

880 958

881 959

882 960

883 961

884 962

885 963

886 964

887 965

888 966

889 967

890 968

891 969

892 970

893 971

894 972

895 973

896 974

897 975

898 976

899 977

900 978

901 979

902 980

903 981

904 982

905 983

906 984

907 985

908 986

909 987

910 988

911 989

912 990

913 991

914 992

915 993

916 994

917 995

918 996

919 997

920 998

921 999

922 1000

923 1001

924 1002

925 1003

926 1004

927 1005

928 1006

929 1007

930 1008

931 1009

932 1010

933 1011

934 1012

935 1013

936 1014

937 1015

938 1016

939 1017

940 1018

941 1019

942 1020

943 1021

944 1022

945 1023

946 1024

947 1025

948 1026

949 1027

950 1028

951 1029

952 1030

953 1031

954 1032

955 1033

956 1034

957 1035

958 1036

959 1037

960 1038

961 1039

962 1040

963 1041

964 1042

965 1043

966 1044

967 1045

968 1046

969 1047

970 1048

971 1049

972 1050

973 1051

974 1052

975 1053

976 1054

977 1055

978 1056

979 1057

980 1058

981 1059

982 1060

983 1061

984 1062

985 1063

986 1064

987 1065

988 1066

989 1067

990 1068

991 1069

992 1070

993 1071

994 1072

995 1073

996 1074

997 1075

998 1076

999 1077

1000 1078

1001 1079

1002 1080

1003 1081

1004 1082

1005 1083

1006 1084

1007 1085

1008 1086

1009 1087

1010 1088

1011 1089

1012 1090

1013 1091

1014 1092

1015 1093

1016 1094

1017 1095

1018 1096

1019 1097

1020 1098

1021 1099

1022 1100

1023 1101

1024 1102

10

including the randomization process, allocation concealment, blinding of participants, outcome evaluation, fully addressed outcome data, selective outcome reporting, and other sources of bias. Using ROBINS-1, bias of all nonrandomized controlled studies was evaluated, including bias due to confounding, selection bias, bias in classification of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in measurement of outcomes and bias in selection of the reported result. When a dispute between two reviewers cannot be resolved through dialogue, an adjudicator will be called in to aid.

Data synthesis

Qualitative synthesis

We will qualitatively analyze the studies and their results in accordance with Standard 4.2 and Chapter 4 of Finding What Works in Health Care: Standards for Systematic Review [20]. We will analyze the studies following the study outcomes, discuss the details of each performance of cannabis and cannabinoids in alleviating dermatological conditions or diseases, and evaluate the risk of bias.

Quantitative synthesis

If the study includes a control group, we will evaluate the efficacy of medical cannabis or cannabinoids in alleviating skin conditions between case and control, as well as between pre- and post-cannabinoids applications. If the study lacks a control group, we will only compare pre- and post-performance. We will combine the study results for each outcome reported in common by two or more studies using the standard mean difference (SMD) method for continuous outcomes and the relative risk (RR) method for dichotomous outcomes. For continuous outcomes in studies with controls, we will utilize the standard mean difference (SMD) of the difference between the case's pre- and post-performance and the control's pre- and post-performance to eliminate baseline heterogeneity between case and control. To compare findings before and after cannabinoid treatment, we will use the standard mean difference (SMD) of outcomes before and after cannabinoid administration. The pooled effect sizes and 95% confidence intervals (CI) will be calculated using random effects models.

For continuous outcomes measured on different scales, in addition to the standard mean difference (SMD) approach for standardization [21], we will attempt to employ the odd ratio method (OR) by specifying the cutoff of the outcome and converting all continuous measures to binary scale, which are 'improvement' and 'no improvement'. We will seek the raw data from the respective authors by contacting them. If we were unable to get the response within 14 days, we will perform the analysis using only the available data.

RevMan 5.4 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) will be used to perform the meta-analysis. P-value < 0.05 will be considered statistically significant.

Assessment of heterogeneity

Heterogeneity will be determined using the Cochran's Q test [a p-value of 0.10 indicated heterogeneity] and the Higgins' test [I²] [less than 25%: low heterogeneity, 25–75%: moderate heterogeneity, more than 75%: high heterogeneity] [22].

Sensitivity analysis and Publication bias

1
2 176 Sensitivity analyzes will examine redoing the meta-analysis by removing one research at a
3 177 time to assess the statistical robustness of the primary outcome. The Egger’s regression
4 178 asymmetry test and funnel plots will be considered to assess publication bias using R
5 179 version 4.0.1 if the number of identified studies is fewer than 10.

7
8 180 **Patients and Public Involvement**

9 181 Patients or the public were not involved in the design, or conduct, or reporting, or
10 182 dissemination plans of our research.

12
13 183 **Discussion**

14 184 Pathological investigations have suggested that cannabis and cannabinoids may be
15 185 beneficial in the treatment of dermatological problems. However, there is insufficient
16 186 agreement on their true therapeutic applicability. Previous scoping studies and systematic
17 187 reviews may have focused on different types of skin disorders; nevertheless, quantitative
18 188 meta-analysis and systematic reviews based primarily on skin problems tend to be
19 189 restricted, particularly when dividing the measured results into subjective, objective and
20 190 disease-specific composite scores. Reporting the efficacy of the treatment in the
21 191 aforementioned characteristics can make the findings in this study easier to apply, since
22 192 this quantitative reporting can be easier to comprehend and reproduce for future extended
23 193 research and decreases the biased bias of the authors, and because a skin condition is
24 194 identified in many skin diseases. This systematic review and meta-analysis aims to provide
25 195 a comprehensive summary of the therapeutic effects of cannabis and cannabinoids on
26 196 dermatological conditions and diseases. This informs clinicians and patients about the
27 197 efficacy of cannabis and cannabinoids in skin disorders and identifies information gaps
28 198 that may lead to the creation of a new alternative therapy for dermatological diseases.
31 199

32 200 **Data Availability**

33 201 All data produced in the present study are available upon reasonable request to the
34 202 authors.

36 204 **Funding Statement**

37 205 This study did not receive any funding.

40 207 **Authors’ contributions**

41 208 PS, TN, CS, KC and KP conceived of the study and initiated the study design. PS wrote
42 209 original draft. KP review and edit the draft. KP supervised. All authors contributed to the
43 210 refinement of the study protocol.
44 211

45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Ensignment Superior (ABES).

References

1. Lee HJ, Kim M. Skin Barrier Function and the Microbiome. *International journal of molecular sciences*. 2022;23(21). Epub 2022/11/12. doi: 10.3390/ijms232113071. PubMed PMID: 36361857; PubMed Central PMCID: PMCPCMC9654002.
2. Wong DJ, Chang HY. *Skin tissue engineering*. StemBook. Cambridge (MA): Harvard Stem Cell Institute; 2008.
3. Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. *International journal of molecular sciences*. 2021;22(17). Epub 2021/09/11. doi: 10.3390/ijms22179472. PubMed PMID: 34502379; PubMed Central PMCID: PMCPCMC8430969.
4. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacological reviews*. 2006;58(3):389-462. Epub 2006/09/14. doi: 10.1124/pr.58.3.2. PubMed PMID: 16968947; PubMed Central PMCID: PMCPCMC2241751.
5. Joshi N, Onaivi ES. Endocannabinoid System Components: Overview and Tissue Distribution. *Advances in experimental medicine and biology*. 2019;1162:1-12. Epub 2019/07/25. doi: 10.1007/978-3-030-21737-2_1. PubMed PMID: 31332731.
6. Meah F, Lundholm M, Emanuele N, Amjed H, Poku C, Agrawal L, et al. The effects of cannabis and cannabinoids on the endocrine system. *Reviews in endocrine & metabolic disorders*. 2022;23(3):401-20. Epub 2021/08/31. doi: 10.1007/s11154-021-09682-w. PubMed PMID: 34460075.
7. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clinical pharmacokinetics*. 2003;42(4):327-60. Epub 2003/03/22. doi: 10.2165/00003088-200342040-00003. PubMed PMID: 12648025.
8. Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. Marijuana Legalization: Impact on Physicians and Public Health. *Annual review of medicine*. 2016;67:453-66. Epub 2015/10/31. doi: 10.1146/annurev-med-050214-013454. PubMed PMID: 26515984; PubMed Central PMCID: PMCPCMC4900958.
9. Schlag AK. An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK? *Medical cannabis and cannabinoids*. 2020;3(1):76-83. Epub 2020/01/15. doi: 10.1159/000505028. PubMed PMID: 34676342; PubMed Central PMCID: PMCPCMC8489334.
10. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. *Nature reviews Drug discovery*. 2004;3(9):771-84. Epub 2004/09/02. doi: 10.1038/nrd1495. PubMed PMID: 15340387.
11. Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: Therapeutic Use in Clinical Practice. *International journal of molecular sciences*. 2022;23(6). Epub

2022/03/26. doi: 10.3390/ijms23063344. PubMed PMID: 35328765; PubMed Central PMCID: PMCPMC8952215.

12. Norooznezhad AH, Norooznezhad F. Cannabinoids: Possible agents for treatment of psoriasis via suppression of angiogenesis and inflammation. *Medical hypotheses*. 2017;99:15-8. Epub 2017/01/24. doi: 10.1016/j.mehy.2016.12.003. PubMed PMID: 28110689.

13. Kim HJ, Kim B, Park BM, Jeon JE, Lee SH, Mann S, et al. Topical cannabinoid receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced atopic dermatitis model. *International journal of dermatology*. 2015;54(10):e401-8. Epub 2015/06/23. doi: 10.1111/ijd.12841. PubMed PMID: 26095080.

14. Shao K, Stewart C, Grant-Kels JM. Cannabis and the skin. *Clinics in dermatology*. 2021;39(5):784-95. Epub 2021/11/18. doi: 10.1016/j.clindermatol.2021.05.006. PubMed PMID: 34785006.

15. Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllösi AG, Czifra G, et al. Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. *The Journal of clinical investigation*. 2014;124(9):3713-24. Epub 2014/07/26. doi: 10.1172/jci64628. PubMed PMID: 25061872; PubMed Central PMCID: PMCPMC4151231.

16. Bilir KA, Anli G, Ozkan E, Gunduz O, Ulugol A. Involvement of spinal cannabinoid receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist. *Clinical and experimental dermatology*. 2018;43(5):553-8. Epub 2018/02/10. doi: 10.1111/ced.13398. PubMed PMID: 29424035.

17. Scheau C, Badarau IA, Mihai LG, Scheau AE, Costache DO, Constantin C, et al. Cannabinoids in the Pathophysiology of Skin Inflammation. *Molecules (Basel, Switzerland)*. 2020;25(3). Epub 2020/02/09. doi: 10.3390/molecules25030652. PubMed PMID: 32033005; PubMed Central PMCID: PMCPMC7037408.

18. Avila C, Massick S, Kaffenberger BH, Kwatra SG, Bechtel M. Cannabinoids for the treatment of chronic pruritus: A review. *Journal of the American Academy of Dermatology*. 2020;82(5):1205-12. Epub 2020/01/29. doi: 10.1016/j.jaad.2020.01.036. PubMed PMID: 31987788.

19. Covidence systematic review software, Veritas Health Innovation, Melbourne, Australia. [Internet]. Available from: <http://www.covidence.org>.

20. Chen F, Kantagowit P, Nopsopon T, Chuklin A, Pongpirul K. Prediction and diagnosis of chronic kidney disease development and progression using machine-learning: protocol for a systematic review and meta-analysis of reporting standards and model performance. *medRxiv*. 2022:2022.11.24.22282661. doi: 10.1101/2022.11.24.22282661.

21. Murad MH, Wang Z, Chu H, Lin L. When continuous outcomes are measured using different scales: guide for meta-analysis and interpretation. *BMJ (Clinical research ed)*. 2019;364:k4817. Epub 2019/01/24. doi: 10.1136/bmj.k4817. PubMed PMID: 30670455.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies. Ensignment Supérieur (ABES).

For peer review only

22. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in medicine*. 2002;21(11):1539-58. Epub 2002/07/12. doi: 10.1002/sim.1186. PubMed PMID: 12111919.

Cannabis and cannabinoids in dermatology: A systematic review and meta-analysis of quantitative outcomes

Concept 1: Cannabinoid
Concept 2: Dermatology

Set #	Pubmed (until 9 Nov 2022)
1 Cannabinoids	"cannabis"[MeSH Terms] OR cannabis[tiab] OR canabis[tiab] OR "cannabaceae"[MeSH Terms:noexp] OR cannabaceae[tiab] OR hemp*[tiab] OR marijuana[tiab] OR marihuana[tiab] OR ganja*[tiab] OR hash[tiab] OR hashish[tiab] OR bhang[tiab] OR skunk[tiab] OR sinsemilla[tiab] OR charas[tiab] OR weed*[tiab] OR "cannabinoids"[MeSH Terms] OR cannabinoid*[tiab] OR canabinoid*[tiab] OR cannabidiol*[tiab] OR canabidiol*[tiab] OR cannabinol[tiab] OR cannador[tiab] OR eucannabinolide[tiab] OR "8001-45-4"[tiab] OR "8063-14-7"[tiab] OR "38458-58-1"[tiab] OR "dronabinol"[MeSH Terms] OR dronabinol*[tiab] OR marinol[tiab] OR deltanyne[tiab] OR ea1477[tiab] OR "ea-1477"[tiab] OR tetranabinex[tiab] OR qcd84924[tiab] OR "qcd-84924"[tiab] OR "7663-50-5"[tiab] OR nabidiolex[tiab] OR "13956-29-1"[tiab] OR "nabilone"[Supplementary Concept] OR nabilone[tiab] OR cesamet*[tiab] OR cpd109514[tiab] OR "cpd-109514"[tiab] OR lilly109514[tiab] OR "lilly-109514"[tiab] OR "51022-71-0"[tiab] OR "HU 211"[Supplementary Concept] OR "HU 211"[tiab] OR "HU-211"[tiab] OR hu211[tiab] OR "HU 210"[tiab] OR "HU-210"[tiab] OR hu210[tiab] OR dexanabinol[tiab] OR "112924-45-5"[tiab] OR "tetrahydrocannabinol-cannabidiol combination"[Supplementary Concept] OR "tetrahydrocannabinol-cannabidiol combination"[tiab] OR nabiximol*[tiab] OR sativex[tiab] OR gw1000[tiab] OR "gw-1000"[tiab] OR sab378[tiab] OR "sab-378"[tiab] OR "56575-23-6"[tiab] OR tetrahydrocannabinol*[tiab] OR "tetra-hydrocannabinol"[tiab] OR 9tetrahydrocannabinol[tiab] OR "delta3-THC"[tiab] OR "delta-3-THC"[tiab] OR "delta-3-tetrahydrocannabinol"[tiab] OR sp104[tiab] OR "sp-104"[tiab] OR "1972-08-3"[tiab] OR "delta9-THC"[tiab] OR "delta-9-THC"[tiab] OR "delta-9-tetrahydrocannabinol"[tiab] OR "5957-75-5"[tiab] OR cannabichromene[tiab] OR "521-35-7"[tiab] OR "8-THC"[tiab] OR tetrahydrocannabivarin[tiab] OR anandamide[tiab] OR "n-arachidonylethanolamine"[tiab] OR nantradol[tiab] OR cp44001[tiab] OR "cp-44001"[tiab] OR cp440011[tiab] OR "cp-44001-1"[tiab] OR "cp44001-1"[tiab] OR "72028-54-7"[tiab] OR endocannabinoid*[tiab] OR phytocannabinoid*[tiab] OR sydos[tiab] OR indica[tiab] OR THC[tiab] OR CBD[tiab] OR AEA[tiab]
2 Dermatology	"dermatology"[MeSH Terms] OR dermatol*[tiab] OR "skin"[MeSH Terms] OR skin[tiab] OR cutaneous[tiab] OR wound*[tiab] OR "ulcer"[MeSH Terms] OR ulcer[tiab]
3	#1 AND #2
4	animals[MeSH Terms] NOT humans[MeSH Terms]
5	#3 NOT #4
6	english[lang]
7	#5 AND #6
8	1945/1/01:2022/11/09[dp]
9	#7 AND #8

Set #	Embase (until 9 Nov 2022)
1 Cannabinoids	'cannabis'/exp OR 'cannabis':ti,ab OR 'canabis':ti,ab OR 'cannabaceae'/de OR 'cannabaceae':ti,ab OR 'hemp*':ti,ab OR 'marijuana':ti,ab OR 'marihuana':ti,ab OR 'ganja*':ti,ab OR 'hash':ti,ab OR 'hashish':ti,ab OR 'bhang':ti,ab OR 'skunk':ti,ab OR 'sinsemilla':ti,ab OR 'charas':ti,ab OR 'weed*':ti,ab OR 'cannabinoid'/exp OR 'cannabinoid*':ti,ab OR 'canabinoid*':ti,ab OR 'cannabidiol*':ti,ab OR 'canabidiol*':ti,ab OR 'cannabinol':ti,ab OR 'cannador':ti,ab OR 'eucannabinolide':ti,ab OR '8001-45-4':ti,ab OR '8063-14-7':ti,ab OR '38458-58-1':ti,ab OR 'dronabinol'/exp OR 'dronabinol*':ti,ab OR 'marinol':ti,ab OR 'deltanyne':ti,ab OR 'ea1477':ti,ab OR 'ea-1477':ti,ab OR 'tetranabinex':ti,ab OR 'qcd84924':ti,ab OR 'qcd-84924':ti,ab OR '7663-50-5':ti,ab OR 'nabidiox':ti,ab OR '13956-29-1':ti,ab OR 'nabilone'/exp OR 'nabilone':ti,ab OR 'cesamet*':ti,ab OR 'cpd109514':ti,ab OR 'cpd-109514':ti,ab OR 'lilly-109514':ti,ab OR '51022-71-0':ti,ab OR 'HU 211':ti,ab OR 'HU-211':ti,ab OR 'hu211':ti,ab OR 'HU 210':ti,ab OR 'HU-210':ti,ab OR 'hu210':ti,ab OR 'dexanabinol'/exp OR 'dexanabinol':ti,ab OR '112924-45-5':ti,ab OR 'tetrahydrocannabinol-cannabidiol combination':ti,ab OR 'nabiximol*':ti,ab OR 'sativex':ti,ab OR 'gw1000':ti,ab OR 'gw-1000':ti,ab OR 'sab378':ti,ab OR 'sab-378':ti,ab OR '56575-23-6':ti,ab OR 'tetrahydrocannabinol*':ti,ab OR 'tetra-hydrocannabinol':ti,ab OR '9tetrahydrocannabinol':ti,ab OR 'delta3-THC':ti,ab OR 'delta-3-THC':ti,ab OR 'delta-3-tetrahydrocannabinol':ti,ab OR 'sp104':ti,ab OR 'sp-104':ti,ab OR '1972-08-3':ti,ab OR 'delta9-THC':ti,ab OR 'delta-9-THC':ti,ab OR 'delta-9-tetrahydrocannabinol':ti,ab OR '5957-75-5':ti,ab OR 'cannabichromene':ti,ab OR '521-35-7':ti,ab OR '8-THC':ti,ab OR 'tetrahydrocannabivarin':ti,ab OR 'anandamide':ti,ab OR 'n-arachidonylethanolamine':ti,ab OR 'nantradol':ti,ab OR 'cp44001':ti,ab OR 'cp-44001':ti,ab OR 'cp440011':ti,ab OR 'cp-44001-1':ti,ab OR 'cp44001-1':ti,ab OR '72028-54-7':ti,ab OR 'endocannabinoid*':ti,ab OR 'phytocannabinoid*':ti,ab OR 'sydros':ti,ab OR 'indica':ti,ab OR 'THC':ti,ab OR 'CBD':ti,ab OR 'AEA':ti,ab
2 Dermatology	'dermatology'/exp OR 'dermatol*':ti,ab OR 'skin'/exp OR 'skin':ti,ab OR 'cutaneous':ti,ab OR 'wound*':ti,ab OR 'ulcer'/exp OR 'ulcer':ti,ab
3	#1 AND #2
4	[animals]/lim NOT [humans]/lim
5	#3 NOT #4
6	english:la
7	#5 AND #6
8	[09-11-2022]/sd
9	#7 AND #8

Set #	Scopus (until Nov 2022)
1 Cannabinoids	TITLE-ABS-KEY(cannabis OR cannabis OR cannabaceae OR hemp* OR marijuana OR marihuana OR ganja* OR hash OR hashish OR bhang OR skunk OR sinsemilla OR charas OR weed* OR cannabinoid* OR canabinoid* OR cannabidiol* OR canabidiol* OR cannabinol OR cannador OR eucannabinolide OR "8001-45-4" OR "8063-14-7" OR "38458-58-1" OR dronabinol* OR marinol OR deltanyne OR ea1477 OR "ea-1477" OR tetranabinex OR qcd84924 OR "qcd-84924" OR "7663-50-5" OR nabidiolex OR "13956-29-1" OR nabilone OR cesamet* OR cpd109514 OR "cpd-109514" OR lilly109514 OR "lilly-109514" OR "51022-71-0" OR "HU 211" OR "HU-211" OR hu211 OR "HU 210" OR "HU-210" OR hu210 OR dexanabinol OR "112924-45-5" OR "tetrahydrocannabinol-cannabidiol combination" OR nabiximol* OR sativex OR gw1000 OR "gw-1000" OR sab378 OR "sab-378" OR "56575-23-6" OR tetrahydrocannabinol* OR "tetra-hydrocannabinol" OR 9tetrahydrocannabinol OR "delta3-THC" OR "delta-3-THC" OR "delta-3-tetrahydrocannabinol" OR sp104 OR "sp-104" OR "1972-08-3" OR "delta9-THC" OR "delta-9-THC" OR "delta-9-tetrahydrocannabinol" OR "5957-75-5" OR cannabichromene OR "521-35-7" OR "8-THC" OR tetrahydrocannabivarin OR anandamide OR "n-arachidonylethanolamine" OR nantradol OR cp44001 OR "cp-44001" OR cp440011 OR "cp-44001-1" OR "cp44001-1" OR "72028-54-7" OR endocannabinoid* OR phytocannabinoid* OR sydos OR indica OR THC OR CBD OR AEA)
2 Dermatology	TITLE-ABS-KEY(dermatol* OR skin OR cutaneous OR wound* OR ulcer)
3	#1 AND #2
4	ALL(animals AND NOT humans)
5	#3 AND NOT #4
6	LANGUAGE(english)
7	#5 AND #6
8	PUBYEAR BEF 2023
9	PUBDATETXT(December 2022)
10	#8 AND NOT #9
11	#7 AND #10

Set #	Web of Science (until Dec 2022)
1 Cannabinoids	TS=(cannabis OR cannabis OR cannabaceae OR hemp* OR marijuana OR marihuana OR ganja* OR hash OR hashish OR bhang OR skunk OR sinsemilla OR charas OR weed* OR cannabinoid* OR canabinoid* OR cannabidiol* OR canabidiol* OR cannabinol OR cannador OR eucannabinolide OR "8001-45-4" OR "8063-14-7" OR "38458-58-1" OR dronabinol* OR marinol OR deltanyne OR ea1477 OR "ea-1477" OR tetranabinex OR qcd84924 OR "qcd-84924" OR "7663-50-5" OR nabidiolex OR "13956-29-1" OR nabilone OR cesamet* OR cpd109514 OR "cpd-109514" OR lilly109514 OR "lilly-109514" OR "51022-71-0" OR "HU 211" OR "HU-211" OR hu211 OR "HU 210" OR "HU-210" OR hu210 OR dexanabinol OR "112924-45-5" OR "tetrahydrocannabinol-cannabidiol combination" OR nabiximol* OR sativex OR gw1000 OR "gw-1000" OR sab378 OR "sab-378" OR "56575-23-6" OR tetrahydrocannabinol* OR "tetra-hydrocannabinol" OR 9tetrahydrocannabinol OR "delta3-THC" OR "delta-3-THC" OR "delta-3-tetrahydrocannabinol" OR sp104 OR "sp-104" OR "1972-08-3" OR "delta9-THC" OR "delta-9-THC" OR "delta-9-tetrahydrocannabinol" OR "5957-75-5" OR cannabichromene OR "521-35-7" OR "8-THC" OR tetrahydrocannabivarin OR anandamide OR "n-arachidonylethanolamine" OR nantradol OR cp44001 OR "cp-44001" OR cp440011 OR "cp-44001-1" OR "cp44001-1" OR "72028-54-7" OR endocannabinoid* OR phytocannabinoid* OR sydos OR indica OR THC OR CBD OR AEA)
2 Dermatology	TS=(dermatol* OR skin OR cutaneous OR wound* OR ulcer)
3	#1 AND #2
4	ALL=(animal NOT human)
5	#3 NOT #4
6	LA=(English)
7	#5 AND #6
8	PY=2023
9	#7 NOT #8

Set #	CENTRAL (until Nov 2022)
1 Cannabinoids	[mh "cannabis"] OR cannabis:ti,ab,kw OR canabis:ti,ab,kw OR [mh "cannabaceae"] OR cannabaceae:ti,ab,kw OR hemp*:ti,ab,kw OR marijuana:ti,ab,kw OR marihuana:ti,ab,kw OR ganja*:ti,ab,kw OR hash:ti,ab,kw OR hashish:ti,ab,kw OR bhang:ti,ab,kw OR skunk:ti,ab,kw OR sinsemilla:ti,ab,kw OR charas:ti,ab,kw OR weed*:ti,ab,kw OR [mh "cannabinoids"] OR cannabinoid*:ti,ab,kw OR canabinoid*:ti,ab,kw OR cannabidiol*:ti,ab,kw OR canabidiol*:ti,ab,kw OR cannabinol:ti,ab,kw OR cannador:ti,ab,kw OR eucannabinolide:ti,ab,kw OR "8001-45-4":ti,ab,kw OR "8063-14-7":ti,ab,kw OR "38458-58-1":ti,ab,kw OR [mh "dronabinol"] OR dronabinol*:ti,ab,kw OR marinol:ti,ab,kw OR deltanyne:ti,ab,kw OR ea1477:ti,ab,kw OR "ea-1477":ti,ab,kw OR tetranabinex:ti,ab,kw OR qcd84924:ti,ab,kw OR "qcd-84924":ti,ab,kw OR "7663-50-5":ti,ab,kw OR nabidiox:ti,ab,kw OR "13956-29-1":ti,ab,kw OR nabilone:ti,ab,kw OR cesamet*:ti,ab,kw OR cpd109514:ti,ab,kw OR "cpd-109514":ti,ab,kw OR lilly109514:ti,ab,kw OR "lilly-109514":ti,ab,kw OR "51022-71-0":ti,ab,kw OR "HU 211":ti,ab,kw OR "HU-211":ti,ab,kw OR hu211:ti,ab,kw OR "HU 210":ti,ab,kw OR "HU-210":ti,ab,kw OR hu210:ti,ab,kw OR dexamabinol:ti,ab,kw OR "112924-45-5":ti,ab,kw OR "tetrahydrocannabinol-cannabidiol combination":ti,ab,kw OR nabiximol*:ti,ab,kw OR sativex:ti,ab,kw OR gw1000:ti,ab,kw OR "gw-1000":ti,ab,kw OR sab378:ti,ab,kw OR "sab-378":ti,ab,kw OR "56575-23-6":ti,ab,kw OR tetrahydrocannabinol*:ti,ab,kw OR "tetrahydrocannabinol":ti,ab,kw OR 9tetrahydrocannabinol:ti,ab,kw OR "delta3-THC":ti,ab,kw OR "delta-3-THC":ti,ab,kw OR "delta-3-tetrahydrocannabinol":ti,ab,kw OR sp104:ti,ab,kw OR "sp-104":ti,ab,kw OR "1972-08-3":ti,ab,kw OR "delta9-THC":ti,ab,kw OR "delta-9-THC":ti,ab,kw OR "delta-9-tetrahydrocannabinol":ti,ab,kw OR "5957-75-5":ti,ab,kw OR cannabichromene:ti,ab,kw OR "521-35-7":ti,ab,kw OR "8-THC":ti,ab,kw OR tetrahydrocannabivarin:ti,ab,kw OR anandamide:ti,ab,kw OR "n-arachidonylethanolamine":ti,ab,kw OR nantradol:ti,ab,kw OR cp44001:ti,ab,kw OR "cp-44001":ti,ab,kw OR cp440011:ti,ab,kw OR "cp-44001-1":ti,ab,kw OR "cp44001-1":ti,ab,kw OR "72028-54-7":ti,ab,kw OR endocannabinoid*:ti,ab,kw OR phytocannabinoid*:ti,ab,kw OR sydros:ti,ab,kw OR indica:ti,ab,kw OR THC:ti,ab,kw OR CBD:ti,ab,kw OR AEA:ti,ab,kw
2 Dermatology	[mh "dermatology"] OR dermatol*:ti,ab,kw OR [mh "skin"] OR skin:ti,ab,kw OR cutaneous:ti,ab,kw OR wound*:ti,ab,kw OR [mh "ulcer"] OR ulcer:ti,ab,kw
3	#1 AND #2
4	Limit to Jan 1996-Nov 2022

PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 1 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1-2
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number	<input checked="" type="checkbox"/>	<input type="checkbox"/>	29
Abstract					
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	4-19
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	203-206
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
Support					
Sources	5a	Indicate sources of financial or other support for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	201
Sponsor	5b	Provide name for the review funder and/or sponsor	<input checked="" type="checkbox"/>	<input type="checkbox"/>	201
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	38-58
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	58-60
METHODS					

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	68-77
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	93-94, 124-126
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	92-97
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	100-102
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	104-112
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	114-126
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	116-124
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	80-90
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	128-138
DATA					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	<input checked="" type="checkbox"/>	<input type="checkbox"/>	148-152
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	151-173
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	140-145
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	174-179
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	

BMJ Open

Cannabis and cannabinoids in dermatology: protocol for a systematic review and meta-analysis of quantitative outcomes.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2023-075007.R1
Article Type:	Protocol
Date Submitted by the Author:	08-Aug-2023
Complete List of Authors:	Sermsaksasithorn, Pim; Chulalongkorn University Faculty of Medicine Nopsohon, Tanawin; Brigham and Women's Hospital Department of Medicine Samuthpongton, Chatpol; Chulalongkorn University Faculty of Medicine Chotirosniramit, Korn; Chulalongkorn University Faculty of Medicine Pongpirul, Krit; Chulalongkorn University Faculty of Medicine, Center of Excellence in Preventive & Integrative Medicine and Department of Preventive and Social Medicine; Johns Hopkins University Bloomberg School of Public Health, Department of International Health
Primary Subject Heading:	Dermatology
Secondary Subject Heading:	Addiction, Complementary medicine, Pharmacology and therapeutics
Keywords:	Dermatology < INTERNAL MEDICINE, COMPLEMENTARY MEDICINE, Psoriasis < DERMATOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cannabis and cannabinoids in dermatology: protocol for a systematic review and meta-analysis of quantitative outcomes.

Pim Sermsaksasithorn^{1,2}, Tanawin Nopsopon^{1,2,3}, Chatpol Samuthpongton^{1,2}, Korn Chotirosniramit^{1,2}, Krit Pongpirul^{1,2,4,5,6,7*}

¹ Department of Preventive and Social Medicine, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand.

² School of Global Health, Chulalongkorn University Faculty of Medicine, Bangkok, Thailand.

³ Division of Allergy and Clinical Immunology, Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.

⁴ Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

⁵ Department of Infection Biology & Microbiomes, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK.

⁶ Clinical and Research Center, Bumrungrad International Hospital, Bangkok, Thailand.

⁷ Center of Excellence in Preventive & Integrative Medicine (CE-PIM), Bangkok, Thailand.

* Corresponding author Email: doctorkrit@gmail.com

Abstract

Introduction: Following the discovery of various effects on skin function by modifying endocannabinoid systems, multiple preclinical studies have revealed the promise of cannabis and cannabinoids in the treatment of a variety of skin diseases. However, its clinical efficacy is still debated.

Methods and analysis: The protocol has been prepared using the Preferred Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines. A systematic search will be conducted using PubMed, EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science. We will include randomised controlled trials and observational studies investigating alterations to dermatological characteristics following administration of cannabis and cannabinoids for dermatological diseases and disorders. The two reviewers will perform both the title and abstract and full-text screenings. The Cochrane Risk-of-Bias 2 (RoB2) and ROBINS-1 tools will be used to evaluate the risk of bias. If a group of comparable studies for each quantitative outcome can be discovered, we will conduct a random effects meta-analysis. We will investigate heterogeneity using a combination of visual inspection of the forest plot, the Cochran's Q test and Higgins' test [12]. Sensitivity analyzes will be performed to assess the statistical robustness of the primary outcome. To evaluate a publication bias, the Egger's regression asymmetry test and funnel plots will be considered.

Ethics and dissemination: This study does not require ethical approval because no original data will be collected. The findings will be presented at conferences and published in peer-reviewed journals.

PROSPERO registration number: CRD42023397189.

Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies.
Enseignement Supérieur (ABES).

Strengths

- Focused on skin issues rather than skin diseases, making it easier to apply because many skin diseases share the same skin problem.
- Quantitative reporting of skin improvement results reduces author bias and simplifies future research.
- Classifying quantitative data as subjective, objective, and disease-related particular composite ratings help readers evaluate outcomes reliability.

Limitations

- Recent interest in cannabis for skin improvement and the restrictions of cannabis legalisation in some countries may limit the amount of studies on this topic, especially randomised controlled trials with large sample sizes.

Introduction

Skin is the largest human organ and is essential for organism survival. It is the first line of immunological and physical protection against the external environment, including heat control and retention of hydration (1, 2). A substantial part of the population is affected by skin diseases that have significant effects on the quality of life of sufferers (3-10).

The Endocannabinoid System (ECS), a complex neuromodulatory signalling network, maintains homeostasis and the balance of multiple biological functions by binding ligands (endocannabinoids) to receptors in the nervous system and peripheral organs (6-8). Cannabinoids and active components of *Cannabis sativa*, which were found to mimic endocannabinoid signaling and influence receptor expression (9, 10), have gained interest as potential treatment for various diseases (6, 8). The growing legalization of medicinal cannabis and cannabinoids led to the search for medicinal use in clinical practice. The FDA currently approves the use of cannabinoid to alleviate pain and spasticity in multiple sclerosis and the treatment of chemotherapy-induced nausea and vomiting in cancer patients (11-14).

Modulation of the activity of the endocannabinoid system may influence several types of skin disease, including atopic dermatitis, psoriasis, acne, and skin tumors, according to the etiology of the diseases (15-18). Furthermore, cannabis has been found to possess anti-inflammatory and anti-pruritic properties (13, 19-21), as well as a few more uncommon ones like anti-hydrosis (22). This makes the cannabinoids and active components of *Cannabis sativa* promising for the therapeutic treatment of the skin disorders mentioned above. Given the insufficient quality clinical studies on this topic, this systematic review aims to examine the efficacy of cannabis and cannabinoids in alleviating dermatological conditions and diseases by highlighting current and historical attempts to collect robust clinical data and identify knowledge gaps.

Material and methods

The protocol followed the Preferred Items for Systematic Review and Meta-analysis Protocols (PRISMA-P) guidelines.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Study Selection

Any randomized controlled trials and observational studies including cross-sectional studies, case-control studies, or cohort studies that investigate the efficacy or effectiveness of any form of medical cannabis or cannabinoid in alleviating dermatological conditions or diseases will be included. Exclusion criteria are (1) in vitro studies, case report, protocol, review article, guideline, editorial, commentary, and letter to editor (2) non-peer-reviewed studies (3) animal studies (4) studies published in non-English.

Study outcome

1. Generic outcomes used to assess improvement in skin conditions:
- a. Subjective clinical or patient-reported outcomes such as pruritus score, erythema grade, and quality of life.
- b. Objective evaluation using standard instruments such as transepidermal water loss, lipid analysis, and skin topography evaluation.
2. Disease specific composite scores, mixed subjective and objective outcomes, such as Psoriasis Area Severity Index (PASI) for psoriasis, Eczema Area and Severity Index (EASI), and SCORing Atopic Dermatitis (SCORAD) for atopic dermatitis, etc.

Search strategy

We will search through five databases: PUBMED, EMBASE, SCOPUS, Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science published from onset until 9 November 2022 which will be updated to prior manuscript submission. The search strategy constructed by two health information specialists with systematic review experience will combine search terms and subject headings (MeSH) related to 'cannabis', 'cannabaceae', 'cannabinoids', 'dronabinol', 'dermatology', 'skin', and 'ulcer' (Supplementary 1).

Study records

Data management

After deriving the studies via the mentioned database, we will import them into Covidence systematic review software, which de-duplicates studies and facilitates study selection (23).

Selection process

The titles and abstracts of the identified citations will be evaluated by independent paired reviewers, and initially, the abstracts that do not report the therapeutic effects of cannabis and cannabinoids in dermatological conditions or diseases will be eliminated.

The included studies will then undergo full text review and the final included study will be selected based on all eligibility criteria. Reasons for study exclusion in this step will be recorded. When differences could not be resolved through dialogue, an adjudicator will be brought in to assist. The PRISMA 2020 flow chart will be created to illustrate the workflow.

Data collection and management

The data extraction criteria will be refined prior to data collection to ensure consistency among reviewers. The extracted data includes (1) study characteristics including authors, year of publication, study design, journal, contact information, country and funding (2)

participant information including mean age, sex, number of participants, type and baseline severity of skin diseases or conditions (3) treatment details including the kind of medical cannabinoid used, additional constituents of intervention products, route of administration and the length of treatment (4) control preparation, route of administration, and duration of application (5) dermatological improvement incorporating results and time points of reported outcome (6) missing data (7) interpretation and discussion (8) all relevant text, tables, and figures. We will contact the corresponding authors of the included studies to obtain incompletely reported data. If no response is received within 14 days, studies will be carried out using the available data.

Risk of bias

The two reviewers will independently assess the risk of bias. The risk of bias of all randomized controlled studies will be assessed using the Cochrane Risk-of-Bias 2 (RoB2), including the randomization process, allocation concealment, blinding of participants, outcome evaluation, fully addressed outcome data, selective outcome reporting, and other sources of bias. Using ROBINS-1, bias of all nonrandomized controlled studies was evaluated, including bias due to confounding, selection bias, bias in classification of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in measurement of outcomes and bias in selection of the reported result. When a dispute between two reviewers cannot be resolved through dialogue, an adjudicator will be called in to aid.

Data synthesis

Qualitative synthesis

We will qualitatively analyze the studies and their results in accordance with Standard 4.2 and Chapter 4 of Finding What Works in Health Care: Standards for Systematic Review (24). We will analyze the studies following the study outcomes, discuss the details of each performance of cannabis and cannabinoids in alleviating dermatological conditions or diseases, and evaluate the risk of bias.

Quantitative synthesis

If the study includes a control group, we will evaluate the outcomes between case and control, as well as between pre- and post-cannabinoids applications. If the study lacks a control group, we will only compare pre- and post-performance. We will combine the study results for each outcome reported in common by two or more studies using the standard mean difference (SMD) method for continuous outcomes and the relative risk (RR) method for dichotomous outcomes. For continuous outcomes in studies with controls, we will utilize the standard mean difference (SMD) of the difference between the case's pre- and post-performance and the control's pre- and post-performance to eliminate baseline heterogeneity between case and control. To compare findings before and after cannabinoid treatment, we will use the standard mean difference (SMD) of outcomes before and after cannabinoid administration. The pooled effect sizes and 95% confidence intervals (CI) will be calculated using random effects models.

For continuous outcomes measured on different scales, in addition to the standard mean difference (SMD) approach for standardization (25), we will attempt to employ the odd ratio method (OR) by specifying the cutoff of the outcome and converting all continuous measures to binary scale, which are 'improvement' and 'no improvement'. We will seek the

raw data from the respective authors by contacting them. If we were unable to get the response within 14 days, we will perform the analysis using only the available data.

RevMan 5.4 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark) will be used to perform the meta-analysis. P-value < 0.05 will be considered statistically significant.

Assessment of heterogeneity

Heterogeneity will be determined using the Cochran’s Q test [a p-value of 0.10 indicated heterogeneity] and the Higgins’ test [I²] [less than 25%: low heterogeneity, 25–75%: moderate heterogeneity, more than 75%: high heterogeneity] (26).

Sensitivity analysis and Publication bias

Sensitivity analyzes will examine redoing the meta-analysis by removing one research at a time to assess the statistical robustness of the primary outcome. The Egger’s regression asymmetry test and funnel plots will be considered to assess publication bias using R version 4.0.1 if the number of identified studies is fewer than 10.

Expected dates for research

1 September – 31 November 2023

Ethics and dissemination

Because no original data will be collected, this study does not require ethical approval. The results will be presented at conferences and published in journals with peer review.

Patients and Public Involvement

Patients or the public were not involved in the design, or conduct, or reporting, or dissemination plans of our research.

Implications

This systematic review and meta-analysis aims to provide a comprehensive summary of the therapeutic effects of cannabis and cannabinoids on dermatological conditions and diseases. Previous scoping studies and systematic reviews may have focused on different types of skin disorders; nevertheless, quantitative meta-analysis and systematic reviews based primarily on skin problems tend to be restricted, particularly when dividing the measured results into subjective, objective and disease-specific composite scores. Reporting the efficacy of the treatment in the aforementioned characteristics can make the findings in this study easier to apply, since this quantitative reporting can be easier to comprehend and reproduce for future extended research and decreases the biased bias of the authors, and because a skin condition is identified in many skin diseases. This informs clinicians and patients about the efficacy of cannabis and cannabinoids in skin disorders and identifies information gaps that may lead to the creation of a new alternative therapy for dermatological diseases.

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

Funding Statement

This study did not receive any funding.

Competing interest

None declared.

Authors' contributions

PS, TN, CS, KC and KP conceived of the study and initiated the study design. PS wrote original draft. KP review and edit the draft. KP supervised. All authors contributed to the refinement of the study protocol.

References

1. Lee HJ, Kim M. Skin Barrier Function and the Microbiome. *International journal of molecular sciences*. 2022;23(21).
2. Wong DJ, Chang HY. Skin tissue engineering. StemBook. Cambridge (MA): Harvard Stem Cell Institute; 2008.
3. Devane WA, Dysarz FA, 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. *Mol Pharmacol*. 1988;34(5):605-13.
4. Mouslech Z, Valla V. Endocannabinoid system: An overview of its potential in current medical practice. *Neuro Endocrinol Lett*. 2009;30(2):153-79.
5. Lu HC, Mackie K. Review of the Endocannabinoid System. *Biol Psychiatry Cogn Neurosci Neuroimaging*. 2021;6(6):607-15.
6. Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases. *Int J Mol Sci*. 2021;22(17).
7. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. *Pharmacol Rev*. 2006;58(3):389-462.
8. Joshi N, Onaivi ES. Endocannabinoid System Components: Overview and Tissue Distribution. *Adv Exp Med Biol*. 2019;1162:1-12.
9. Meah F, Lundholm M, Emanuele N, Amjed H, Poku C, Agrawal L, et al. The effects of cannabis and cannabinoids on the endocrine system. *Reviews in endocrine & metabolic disorders*. 2022;23(3):401-20.
10. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. *Clinical pharmacokinetics*. 2003;42(4):327-60.
11. Wilkinson ST, Yarnell S, Radhakrishnan R, Ball SA, D'Souza DC. Marijuana Legalization: Impact on Physicians and Public Health. *Annual review of medicine*. 2016;67:453-66.
12. Schlag AK. An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK? *Medical cannabis and cannabinoids*. 2020;3(1):76-83.
13. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. *Nature reviews Drug discovery*. 2004;3(9):771-84.
14. Pagano C, Navarra G, Coppola L, Avilia G, Bifulco M, Laezza C. Cannabinoids: Therapeutic Use in Clinical Practice. *International journal of molecular sciences*. 2022;23(6).

1
2 15. Norooznezhad AH, Norooznezhad F. Cannabinoids: Possible agents for treatment of
3 psoriasis via suppression of angiogenesis and inflammation. Medical hypotheses.
4 2017;99:15-8.
5 16. Kim HJ, Kim B, Park BM, Jeon JE, Lee SH, Mann S, et al. Topical cannabinoid
6 receptor 1 agonist attenuates the cutaneous inflammatory responses in oxazolone-induced
7 atopic dermatitis model. International journal of dermatology. 2015;54(10):e401-8.
8 17. Shao K, Stewart C, Grant-Kels JM. Cannabis and the skin. Clinics in dermatology.
9 2021;39(5):784-95.
10 18. Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllösi AG, Czifra G, et al. Cannabidiol
11 exerts sebostatic and antiinflammatory effects on human sebocytes. The Journal of clinical
12 investigation. 2014;124(9):3713-24.
13 19. Bilir KA, Anli G, Ozkan E, Gunduz O, Ulugol A. Involvement of spinal cannabinoid
14 receptors in the antipruritic effects of WIN 55,212-2, a cannabinoid receptor agonist.
15 Clinical and experimental dermatology. 2018;43(5):553-8.
16 20. Scheau C, Badarau IA, Mihai LG, Scheau AE, Costache DO, Constantin C, et al.
17 Cannabinoids in the Pathophysiology of Skin Inflammation. Molecules (Basel,
18 Switzerland). 2020;25(3).
19 21. Avila C, Massick S, Kaffenberger BH, Kwatra SG, Bechtel M. Cannabinoids for the
20 treatment of chronic pruritus: A review. Journal of the American Academy of Dermatology.
21 2020;82(5):1205-12.
22 22. Kaemmerer T, Clanner-Engelshofen BM, Lesmeister T, French LE, Reinholz M.
23 Cannabinoids in hyperhidrosis. J Dermatolog Treat. 2023;34(1):2127308.
24 23. Covidence systematic review software, Veritas Health Innovation, Melbourne,
25 Australia. [Internet]. Available from: <http://www.covidence.org>.
26 24. Chen F, Kantagowit P, Nopsopon T, Chuklin A, Pongpirul K. Prediction and
27 diagnosis of chronic kidney disease development and progression using machine-learning:
28 protocol for a systematic review and meta-analysis of reporting standards and model
29 performance. medRxiv. 2022:2022.11.24.22282661.
30 25. Murad MH, Wang Z, Chu H, Lin L. When continuous outcomes are measured using
31 different scales: guide for meta-analysis and interpretation. BMJ (Clinical research ed).
32 2019;364:k4817.
33 26. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics
34 in medicine. 2002;21(11):1539-58.
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Cannabis and cannabinoids in dermatology: A systematic review and meta-analysis of quantitative outcomes

Concept 1: Cannabinoid

Concept 2: Dermatology

Set #	Pubmed (until 9 Nov 2022)
1 Cannabinoids	"cannabis"[MeSH Terms] OR cannabis[tiab] OR canabis[tiab] OR "cannabaceae"[MeSH Terms:noexp] OR cannabaceae[tiab] OR hemp*[tiab] OR marijuana[tiab] OR marihuana[tiab] OR ganja*[tiab] OR hash[tiab] OR hashish[tiab] OR bhang[tiab] OR skunk[tiab] OR sinsemilla[tiab] OR charas[tiab] OR weed*[tiab] OR "cannabinoids"[MeSH Terms] OR cannabinoid*[tiab] OR canabinoid*[tiab] OR cannabidiol*[tiab] OR canabidiol*[tiab] OR cannabinol[tiab] OR cannador[tiab] OR eucannabinolide[tiab] OR "8001-45-4"[tiab] OR "8063-14-7"[tiab] OR "38458-58-1"[tiab] OR "dronabinol"[MeSH Terms] OR dronabinol*[tiab] OR marinol[tiab] OR deltanyne[tiab] OR ea1477[tiab] OR "ea-1477"[tiab] OR tetranabinex[tiab] OR qcd84924[tiab] OR "qcd-84924"[tiab] OR "7663-50-5"[tiab] OR nabidiox[tiab] OR "13956-29-1"[tiab] OR "nabilone"[Supplementary Concept] OR nabilone[tiab] OR cesamet*[tiab] OR cpd109514[tiab] OR "cpd-109514"[tiab] OR lilly109514[tiab] OR "lilly-109514"[tiab] OR "51022-71-0"[tiab] OR "HU 211"[Supplementary Concept] OR "HU 211"[tiab] OR "HU-211"[tiab] OR hu211[tiab] OR "HU 210"[tiab] OR "HU-210"[tiab] OR hu210[tiab] OR dextranabinol[tiab] OR "112924-45-5"[tiab] OR "tetrahydrocannabinol-cannabidiol combination"[Supplementary Concept] OR "tetrahydrocannabinol-cannabidiol combination"[tiab] OR nabiximol*[tiab] OR sativex[tiab] OR gw1000[tiab] OR "gw-1000"[tiab] OR sab378[tiab] OR "sab-378"[tiab] OR "56575-23-6"[tiab] OR tetrahydrocannabinol*[tiab] OR "tetra-hydrocannabinol"[tiab] OR 9tetrahydrocannabinol[tiab] OR "delta3-THC"[tiab] OR "delta-3-THC"[tiab] OR "delta-3-tetrahydrocannabinol"[tiab] OR sp104[tiab] OR "sp-104"[tiab] OR "1972-08-3"[tiab] OR "delta9-THC"[tiab] OR "delta-9-THC"[tiab] OR "delta-9-tetrahydrocannabinol"[tiab] OR "5957-75-5"[tiab] OR cannabichromene[tiab] OR "521-35-7"[tiab] OR "8-THC"[tiab] OR tetrahydrocannabivarin[tiab] OR anandamide[tiab] OR "n-arachidonylethanolamine"[tiab] OR nantradol[tiab] OR cp44001[tiab] OR "cp-44001"[tiab] OR cp440011[tiab] OR "cp-44001-1"[tiab] OR "cp44001-1"[tiab] OR "72028-54-7"[tiab] OR endocannabinoid*[tiab] OR phytocannabinoid*[tiab] OR sydos[tiab] OR indica[tiab] OR THC[tiab] OR CBD[tiab] OR AEA[tiab]
2 Dermatology	"dermatology"[MeSH Terms] OR dermatol*[tiab] OR "skin"[MeSH Terms] OR skin[tiab] OR cutaneous[tiab] OR wound*[tiab] OR "ulcer"[MeSH Terms] OR ulcer[tiab]
3	#1 AND #2
4	animals[MeSH Terms] NOT humans[MeSH Terms]
5	#3 NOT #4
6	english[lang]
7	#5 AND #6
8	1945/1/01:2022/11/09[dp]
9	#7 AND #8

Set #	Embase (until 9 Nov 2022)
1 Cannabinoids	'cannabis'/exp OR 'cannabis':ti,ab OR 'canabis':ti,ab OR 'cannabaceae'/de OR 'cannabaceae':ti,ab OR 'hemp*':ti,ab OR 'marijuana':ti,ab OR 'marihuana':ti,ab OR 'ganja*':ti,ab OR 'hash':ti,ab OR 'hashish':ti,ab OR 'bhang':ti,ab OR 'skunk':ti,ab OR 'sinsemilla':ti,ab OR 'charas':ti,ab OR 'weed*':ti,ab OR 'cannabinoid'/exp OR 'cannabinoid*':ti,ab OR 'canabinoid*':ti,ab OR 'cannabidiol*':ti,ab OR 'canabidiol*':ti,ab OR 'cannabinol':ti,ab OR 'cannador':ti,ab OR 'eucannabinolide':ti,ab OR '8001-45-4':ti,ab OR '8063-14-7':ti,ab OR '38458-58-1':ti,ab OR 'dronabinol'/exp OR 'dronabinol*':ti,ab OR 'marinol':ti,ab OR 'deltanyne':ti,ab OR 'ea1477':ti,ab OR 'ea-1477':ti,ab OR 'tetranabinex':ti,ab OR 'qcd84924':ti,ab OR 'qcd-84924':ti,ab OR '7663-50-5':ti,ab OR 'nabidiox':ti,ab OR '13956-29-1':ti,ab OR 'nabilone'/exp OR 'nabilone':ti,ab OR 'cesamet*':ti,ab OR 'cpd109514':ti,ab OR 'cpd-109514':ti,ab OR 'lilly109514':ti,ab OR 'lilly-109514':ti,ab OR '51022-71-0':ti,ab OR 'HU 211':ti,ab OR 'HU-211':ti,ab OR 'hu211':ti,ab OR 'HU 210':ti,ab OR 'HU-210':ti,ab OR 'hu210':ti,ab OR 'dexanabinol'/exp OR 'dexanabinol':ti,ab OR '112924-45-5':ti,ab OR 'tetrahydrocannabinol-cannabidiol combination':ti,ab OR 'nabiximol*':ti,ab OR 'sativex':ti,ab OR 'gw1000':ti,ab OR 'gw-1000':ti,ab OR 'sab378':ti,ab OR 'sab-378':ti,ab OR '56575-23-6':ti,ab OR 'tetrahydrocannabinol*':ti,ab OR 'tetra-hydrocannabinol':ti,ab OR '9tetrahydrocannabinol':ti,ab OR 'delta3-THC':ti,ab OR 'delta-3-THC':ti,ab OR 'delta-3-tetrahydrocannabinol':ti,ab OR 'sp104':ti,ab OR 'sp-104':ti,ab OR '1972-08-3':ti,ab OR 'delta9-THC':ti,ab OR 'delta-9-THC':ti,ab OR 'delta-9-tetrahydrocannabinol':ti,ab OR '5957-75-5':ti,ab OR 'cannabichromene':ti,ab OR '521-35-7':ti,ab OR '8-THC':ti,ab OR 'tetrahydrocannabivarin':ti,ab OR 'anandamide':ti,ab OR 'n-arachidonylethanolamine':ti,ab OR 'nantradol':ti,ab OR 'cp44001':ti,ab OR 'cp-44001':ti,ab OR 'cp440011':ti,ab OR 'cp-44001-1':ti,ab OR 'cp44001-1':ti,ab OR '72028-54-7':ti,ab OR 'endocannabinoid*':ti,ab OR 'phytocannabinoid*':ti,ab OR 'sydros':ti,ab OR 'indica':ti,ab OR 'THC':ti,ab OR 'CBD':ti,ab OR 'AEA':ti,ab
2 Dermatology	'dermatology'/exp OR 'dermatol*':ti,ab OR 'skin'/exp OR 'skin':ti,ab OR 'cutaneous':ti,ab OR 'wound*':ti,ab OR 'ulcer'/exp OR 'ulcer':ti,ab
3	#1 AND #2
4	[animals]/lim NOT [humans]/lim
5	#3 NOT #4
6	english:la
7	#5 AND #6
8	[09-11-2022]/sd
9	#7 AND #8

Set #	Scopus (until Nov 2022)
1 Cannabinoids	TITLE-ABS-KEY(cannabis OR cannabis OR cannabaceae OR hemp* OR marijuana OR marihuana OR ganja* OR hash OR hashish OR bhang OR skunk OR sinsemilla OR charas OR weed* OR cannabinoid* OR canabinoid* OR cannabidiol* OR canabidiol* OR cannabinol OR cannador OR eucannabinolide OR "8001-45-4" OR "8063-14-7" OR "38458-58-1" OR dronabinol* OR marinol OR deltanyne OR ea1477 OR "ea-1477" OR tetranabinex OR qcd84924 OR "qcd-84924" OR "7663-50-5" OR nabidiolex OR "13956-29-1" OR nabilone OR cesamet* OR cpd109514 OR "cpd-109514" OR lilly109514 OR "lilly-109514" OR "51022-71-0" OR "HU 211" OR "HU-211" OR hu211 OR "HU 210" OR "HU-210" OR hu210 OR dextranabinol OR "112924-45-5" OR "tetrahydrocannabinol-cannabidiol combination" OR nabiximol* OR sativex OR gw1000 OR "gw-1000" OR sab378 OR "sab-378" OR "56575-23-6" OR tetrahydrocannabinol* OR "tetra-hydrocannabinol" OR 9tetrahydrocannabinol OR "delta3-THC" OR "delta-3-THC" OR "delta-3-tetrahydrocannabinol" OR sp104 OR "sp-104" OR "1972-08-3" OR "delta9-THC" OR "delta-9-THC" OR "delta-9-tetrahydrocannabinol" OR "5957-75-5" OR cannabichromene OR "521-35-7" OR "8-THC" OR tetrahydrocannabivarin OR anandamide OR "n-arachidonylethanolamine" OR nantradol OR cp44001 OR "cp-44001" OR cp440011 OR "cp-44001-1" OR "cp44001-1" OR "72028-54-7" OR endocannabinoid* OR phytocannabinoid* OR sydos OR indica OR THC OR CBD OR AEA)
2 Dermatology	TITLE-ABS-KEY(dermatol* OR skin OR cutaneous OR wound* OR ulcer)
3	#1 AND #2
4	ALL(animals AND NOT humans)
5	#3 AND NOT #4
6	LANGUAGE(english)
7	#5 AND #6
8	PUBYEAR BEF 2023
9	PUBDATETXT(December 2022)
10	#8 AND NOT #9
11	#7 AND #10

Set #	Web of Science (until Dec 2022)
1 Cannabinoids	TS=(cannabis OR cannabis OR cannabaceae OR hemp* OR marijuana OR marihuana OR ganja* OR hash OR hashish OR bhang OR skunk OR sinsemilla OR charas OR weed* OR cannabinoid* OR canabinoid* OR cannabidiol* OR canabidiol* OR cannabinol OR cannador OR eucannabinolide OR "8001-45-4" OR "8063-14-7" OR "38458-58-1" OR dronabinol* OR marinol OR deltanyne OR ea1477 OR "ea-1477" OR tetranabinex OR qcd84924 OR "qcd-84924" OR "7663-50-5" OR nabidiolex OR "13956-29-1" OR nabilone OR cesamet* OR cpd109514 OR "cpd-109514" OR lilly109514 OR "lilly-109514" OR "51022-71-0" OR "HU 211" OR "HU-211" OR hu211 OR "HU 210" OR "HU-210" OR hu210 OR dexanabinol OR "112924-45-5" OR "tetrahydrocannabinol-cannabidiol combination" OR nabiximol* OR sativex OR gw1000 OR "gw-1000" OR sab378 OR "sab-378" OR "56575-23-6" OR tetrahydrocannabinol* OR "tetra-hydrocannabinol" OR 9tetrahydrocannabinol OR "delta3-THC" OR "delta-3-THC" OR "delta-3-tetrahydrocannabinol" OR sp104 OR "sp-104" OR "1972-08-3" OR "delta9-THC" OR "delta-9-THC" OR "delta-9-tetrahydrocannabinol" OR "5957-75-5" OR cannabichromene OR "521-35-7" OR "8-THC" OR tetrahydrocannabivarin OR anandamide OR "n-arachidonylethanolamine" OR nantradol OR cp44001 OR "cp-44001" OR cp440011 OR "cp-44001-1" OR "cp44001-1" OR "72028-54-7" OR endocannabinoid* OR phytocannabinoid* OR sydos OR indica OR THC OR CBD OR AEA)
2 Dermatology	TS=(dermatol* OR skin OR cutaneous OR wound* OR ulcer)
3	#1 AND #2
4	ALL=(animal NOT human)
5	#3 NOT #4
6	LA=(English)
7	#5 AND #6
8	PY=2023
9	#7 NOT #8

Set #	CENTRAL (until Nov 2022)
1 Cannabinoids	[mh "cannabis"] OR cannabis:ti,ab,kw OR canabis:ti,ab,kw OR [mh "cannabaceae"] OR cannabaceae:ti,ab,kw OR hemp*:ti,ab,kw OR marijuana:ti,ab,kw OR marihuana:ti,ab,kw OR ganja*:ti,ab,kw OR hash:ti,ab,kw OR hashish:ti,ab,kw OR bhang:ti,ab,kw OR skunk:ti,ab,kw OR sinsemilla:ti,ab,kw OR charas:ti,ab,kw OR weed*:ti,ab,kw OR [mh "cannabinoids"] OR cannabinoid*:ti,ab,kw OR canabinoid*:ti,ab,kw OR cannabidiol*:ti,ab,kw OR canabidiol*:ti,ab,kw OR cannabinol:ti,ab,kw OR cannador:ti,ab,kw OR eucannabinolide:ti,ab,kw OR "8001-45-4":ti,ab,kw OR "8063-14-7":ti,ab,kw OR "38458-58-1":ti,ab,kw OR [mh "dronabinol"] OR dronabinol*:ti,ab,kw OR marinol:ti,ab,kw OR deltanyne:ti,ab,kw OR ea1477:ti,ab,kw OR "ea-1477":ti,ab,kw OR tetranabinex:ti,ab,kw OR qcd84924:ti,ab,kw OR "qcd-84924":ti,ab,kw OR "7663-50-5":ti,ab,kw OR nabidiox:ti,ab,kw OR "13956-29-1":ti,ab,kw OR nabilone:ti,ab,kw OR cesamet*:ti,ab,kw OR cpd109514:ti,ab,kw OR "cpd-109514":ti,ab,kw OR lilly109514:ti,ab,kw OR "lilly-109514":ti,ab,kw OR "51022-71-0":ti,ab,kw OR "HU 211":ti,ab,kw OR "HU-211":ti,ab,kw OR hu211:ti,ab,kw OR "HU 210":ti,ab,kw OR "HU-210":ti,ab,kw OR hu210:ti,ab,kw OR dexamabinol:ti,ab,kw OR "112924-45-5":ti,ab,kw OR "tetrahydrocannabinol-cannabidiol combination":ti,ab,kw OR nabiximol*:ti,ab,kw OR sativex:ti,ab,kw OR gw1000:ti,ab,kw OR "gw-1000":ti,ab,kw OR sab378:ti,ab,kw OR "sab-378":ti,ab,kw OR "56575-23-6":ti,ab,kw OR tetrahydrocannabinol*:ti,ab,kw OR "tetrahydrocannabinol":ti,ab,kw OR 9tetrahydrocannabinol:ti,ab,kw OR "delta3-THC":ti,ab,kw OR "delta-3-THC":ti,ab,kw OR "delta-3-tetrahydrocannabinol":ti,ab,kw OR sp104:ti,ab,kw OR "sp-104":ti,ab,kw OR "1972-08-3":ti,ab,kw OR "delta9-THC":ti,ab,kw OR "delta-9-THC":ti,ab,kw OR "delta-9-tetrahydrocannabinol":ti,ab,kw OR "5957-75-5":ti,ab,kw OR cannabichromene:ti,ab,kw OR "521-35-7":ti,ab,kw OR "8-THC":ti,ab,kw OR tetrahydrocannabivarin:ti,ab,kw OR anandamide:ti,ab,kw OR "n-arachidonylethanolamine":ti,ab,kw OR nantradol:ti,ab,kw OR cp44001:ti,ab,kw OR "cp-44001":ti,ab,kw OR cp440011:ti,ab,kw OR "cp-44001-1":ti,ab,kw OR "cp44001-1":ti,ab,kw OR "72028-54-7":ti,ab,kw OR endocannabinoid*:ti,ab,kw OR phytocannabinoid*:ti,ab,kw OR syndros:ti,ab,kw OR indica:ti,ab,kw OR THC:ti,ab,kw OR CBD:ti,ab,kw OR AEA:ti,ab,kw
2 Dermatology	[mh "dermatology"] OR dermatol*:ti,ab,kw OR [mh "skin"] OR skin:ti,ab,kw OR cutaneous:ti,ab,kw OR wound*:ti,ab,kw OR [mh "ulcer"] OR ulcer:ti,ab,kw
3	#1 AND #2
4	Limit to Jan 1996-Nov 2022

PRISMA-P 2015 Checklist

This checklist has been adapted for use with protocol submissions to *Systematic Reviews* from Table 1 in Moher D et al: Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Systematic Reviews* 2015 4:1

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
ADMINISTRATIVE INFORMATION					
Title					
Identification	1a	Identify the report as a protocol of a systematic review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1-3
Update	1b	If the protocol is for an update of a previous systematic review, identify as such	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
Registration	2	If registered, provide the name of the registry (e.g., PROSPERO) and registration number	<input checked="" type="checkbox"/>	<input type="checkbox"/>	49
Abstract					
Authors					
Contact	3a	Provide name, institutional affiliation, and e-mail address of all protocol authors; provide physical mailing address of corresponding author	<input checked="" type="checkbox"/>	<input type="checkbox"/>	4-20
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	266-270
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
Support					
Sources	5a	Indicate sources of financial or other support for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	258-260
Sponsor	5b	Provide name for the review funder and/or sponsor	<input checked="" type="checkbox"/>	<input type="checkbox"/>	232-235
Role of sponsor/funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
INTRODUCTION					
Rationale	6	Describe the rationale for the review in the context of what is already known	<input checked="" type="checkbox"/>	<input type="checkbox"/>	64-92
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	90-92
METHODS					

Section/topic	#	Checklist item	Information reported		Line number(s)
			Yes	No	
Eligibility criteria	8	Specify the study characteristics (e.g., PICO, study design, setting, time frame) and report characteristics (e.g., years considered, language, publication status) to be used as criteria for eligibility for the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	99-107
Information sources	9	Describe all intended information sources (e.g., electronic databases, contact with study authors, trial registers, or other grey literature sources) with planned dates of coverage	<input checked="" type="checkbox"/>	<input type="checkbox"/>	122-124, 157-160
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated	<input checked="" type="checkbox"/>	<input type="checkbox"/>	122-128
STUDY RECORDS					
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review	<input checked="" type="checkbox"/>	<input type="checkbox"/>	132-135
Selection process	11b	State the process that will be used for selecting studies (e.g., two independent reviewers) through each phase of the review (i.e., screening, eligibility, and inclusion in meta-analysis)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	137-144
Data collection process	11c	Describe planned method of extracting data from reports (e.g., piloting forms, done independently, in duplicate), any processes for obtaining and confirming data from investigators	<input checked="" type="checkbox"/>	<input type="checkbox"/>	148-149
Data items	12	List and define all variables for which data will be sought (e.g., PICO items, funding sources), any pre-planned data assumptions and simplifications	<input checked="" type="checkbox"/>	<input type="checkbox"/>	149-157
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale	<input checked="" type="checkbox"/>	<input type="checkbox"/>	1079-118
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis	<input checked="" type="checkbox"/>	<input type="checkbox"/>	162-173
DATA					
Synthesis	15a	Describe criteria under which study data will be quantitatively synthesized	<input checked="" type="checkbox"/>	<input type="checkbox"/>	187-189
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data, and methods of combining data from studies, including any planned exploration of consistency (e.g., I^2 , Kendall's tau)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	188-198, 206-208, 210-214
	15c	Describe any proposed additional analyses (e.g., sensitivity or subgroup analyses, meta-regression)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	218-219
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned	<input checked="" type="checkbox"/>	<input type="checkbox"/>	177-183, 199-205
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (e.g., publication bias across studies, selective reporting within studies)	<input checked="" type="checkbox"/>	<input type="checkbox"/>	219-221
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (e.g., GRADE)	<input type="checkbox"/>	<input checked="" type="checkbox"/>	